Moyou 2001.

Methods	Trial design: randomized controlled trial Generation of allocation sequence: computer‐generated randomization Allocation concealment: sealed, coded envelopes (information provided by author) Blinding: none as different routes of drug administration used Loss to follow up: 2 lost to follow up at day 28 in arteether group
Participants	102 male and female children aged 0 to 10 years with cerebral malaria: 4/106 (4%) excluded; 102 evaluated (arteether (51), quinine (51)) Inclusion criteria: asexual falciparum parasitaemia; Blantyre coma score of 2 or less Exclusion criteria: children presenting with chronic illness, eg renal or liver diseases, frank acquired immune deficiency syndrome (AIDS), epilepsy, and cardiovascular accident/stroke; children taking cardioactive drugs; history of blackwater fever; positive blood culture for a pathogen or positive cerebrospinal fluid test result
Interventions	1. Arteether for 5 days (3.2 mg/kg first day, then 1.6 mg/kg next 4 days) 2. Quinine for 7 days (20 mg/kg loading dose then 10 mg/kg every 8 h thereafter)
Outcomes	1. Mortality 2. Coma resolution time 3. Fever clearance time 4. Parasite clearance time 5. Serious adverse events
Notes	Location: Cameroon